Q3 2019 Investor Presentation slide image

Q3 2019 Investor Presentation

Improving adherence to therapy ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Probability on Therapy (%) 100 100% 0 Resupply group (AirView + Brightree) 90 Control group (non-resupply) Time to Drop out (days) + brightree. AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. © 2019 ResMed I Q3 2019 Investor Presentation | 48 ResMed
View entire presentation